Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Advanced NSCLC × famitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Non Squamous Non Small Cell Lung 1 Gastrointestinal Stromal Tumors 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced NSCLC 1

Interventions

famitinib 1 camrelizumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡